Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Coumarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.77 |
| ▸ | CA12 | O43570 | 12/20 | 0.77 |
| ▸ | CA1 | P00915 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | CA3 | P07451 | 3/20 | 0.77 |
| ▸ | CA4 | P22748 | 3/20 | 0.77 |
| ▸ | CA5A | P35218 | 3/20 | 0.77 |
| ▸ | CA7 | P43166 | 3/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.77 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.77 |
| ▸ | CA2 | P00918 | 2/20 | 0.77 |
| ▸ | CA6 | P23280 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coumarin SCHEMBL28058644 | 0.95 | CA9 (0.69) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL27598031 | 0.94 | CA9 (0.80) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL1090505 | 0.92 | CA12 (0.83) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL25431834 | 0.92 | CA12 (0.91) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL11101317 | 0.90 | CA12 (0.87) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL19183240 | 0.90 | CA12 (0.95) | CA9CA12CA1TDP1CA3 | |
| SCHEMBL7358531 | 0.90 | CA12 (0.95) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL27373119 | 0.90 | CA9 (0.67) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL27601322 | 0.89 | CA9 (0.71) | CA9CA12CA1TDP1CA3 | |
| Coumarin SCHEMBL29078087 | 0.89 | CA12 (0.77) | CA9CA12CA1TDP1CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117789993-B | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-06-11 | — | — | CN | claimed |
| CN-117789993-A | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-03-29 | — | — | CN | claimed |
| CN-110199019-A | Analysis of Macromolecules Using Nucleic Acid Encoding | ENCODIA有限公司 | 2019-09-03 | — | — | CN | claimed |
| CN-108129388-A | A kind of rhodamine double pyrazole acetic acid esters organic laser material and its application | 深圳市佶达德科技有限公司 | 2018-06-08 | — | — | CN | claimed |
| CN-108047211-A | A kind of double pyrazole acetic acid coumarin derivative laser material and its application | 深圳市佶达德科技有限公司 | 2018-05-18 | — | — | CN | claimed |
| US-8735178-B2 | Withanolides, probes and binding targets and methods of use thereof | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-05-27 | — | — | US | claimed |
| CN-1872054-B | Drop pills of coumarin acetic acid, and preparation method | TIANJIN TASLY PHARMACEUTICAL | 2010-11-03 | — | — | CN | claimed |
| US-20080207574-A1 | WITHANOLIDES, PROBES AND BINDING TARGETS AND METHODS OF USE THEREOF | KENTUCKY RESEARCH FOUNDATION | 2008-08-28 | — | — | US | claimed |
| CN-1872054-A | Drop pills of coumarin acetic acid, and preparation method | TIANSHILI PHARM CO LTD (CN) | 2006-12-06 | — | — | CN | claimed |
| CN-1863805-A | Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof | LACER SA (ES) | 2006-11-15 | — | — | CN | claimed |
| CN-1493281-A | Coumarin acetate drip pill and its preparation method | 南昌弘益科技有限公司 | 2004-05-05 | — | — | CN | claimed |
| EP-0975803-A4 | METHOD FOR ASSESSING PROSTATE CANCER | ALBANY MEDICAL COLLEGE (US) | 2002-01-16 | — | — | EP | claimed |
| EP-0975803-A1 | METHOD FOR ASSESSING PROSTATE CANCER | ALBANY MEDICAL COLLEGE (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1998045479-A1 | METHOD FOR ASSESSING PROSTATE CANCER | ALBANY MEDICAL COLLEGE (US) | 1998-10-15 | — | — | WO | claimed |
| US-20250314643-A1 | FLUORESCENT COMPLEXES COMPRISING TWO RHODAMINE DERIVATIVES AND A NUCLEIC ACID MOLECULE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-10-09 | — | — | US | disclosed |
| CN-115851634-B | Application of human CYP2C9 recombinase in denitration of nitrocellulose | 南京理工大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-0277139-B1 | 7-AMINO-4-METHYL-COUMARIN-3-CARBOXYALKYL DERIVATIVES AND FLUORESCENT CONJUGATES THEREOF | BIOCARB AB (SE) | 1990-08-08 | — | — | EP | disclosed |
| EP-0277139-A1 | 7-AMINO-4-METHYL-COUMARIN-3-CARBOXYALKYL DERIVATIVES AND FLUORESCENT CONJUGATES THEREOF. | BIOCARB AB (SE) | 1988-08-10 | — | — | EP | disclosed |
| WO-1987003589-A1 | 7-AMINO-4-METHYL-COUMARIN-3-CABOXYALKYL DERIVATES AND FLUORESCENT CONJUGATES THEREOF | BIOCARB AB (SE) | 1987-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207574-A1 | WITHANOLIDES, PROBES AND BINDING TARGETS AND METHODS OF USE THEREOF | VIM, HASPIN, FABP3 | CA9 3558/4885CA12 3288/4885CA1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.